Verification of drug license & valid prescription is strongly advised for the users before dealing in medicines
Ceftriaxone and Sulbactam Injection
₹ 200/Vial
Usage
Treats various bacterial infections
Strength
1.5 gm
Pack Type
Box
Composition
Ceftriaxonen 1000mg + Sulbactam 500mg
Shelf Life
24 Months
Availability
In Stock
Ceftriaxone & Sulbactam for Injection is indicated in infections caused by Ceftriaxone sodium- sensitive pathogens and may be used in the clinical settings in Sepsis, Meningitis, Abdominal Infections (e.g. Peritonitis, infection of the biliary tract), infections of the Bones, Joints, Soft tissue, Skin and of wounds
Find products similar to Ceftriaxone And Sulbactam Injection
Interested in this product?Get Latest Price from the seller
About the Company
GST Registration Date
01-07-2017
Legal Status of Firm
Proprietorship
Nature of Business
Trader - Wholesaler/Distributor
Number of Employees
Upto 10 People
Annual Turnover
1.5 - 5 Cr
IndiaMART Member Since
Oct 2016
GST
04DKVPK6583C1ZS
We, Romas Remedies from 2018 are manufacturing, trading and wholesaling a high-quality range of Pharmaceutical Products. Offered products range consists of Pharma Franchise Oppturnity, PCD Pharma Franchise In UP and Pharmaceutical Tablets. All offered products are processed under the supervision of our experts by following norms using pure ingredients. In addition to this, these products are known for their high purity, accurate composition, and high effectiveness without causing any side effect. We have made a highly sophisticated infrastructure base. This infrastructure includes manufacturing, research& control, and sales departments. With the help of our professionals, we are fulfilling the needs of patrons by providing optimum quality products. In addition to this, our team encompasses engineers, production experts, quality controllers, research and development experts, administrative personnel, warehousing and packaging personnel, sales and marketing experts, logistics personnel, procurement agents and many others.
